Full-Time

Gxp Laboratory Systems Administrator

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$90k - $115k/yr

Mid, Senior

Fitchburg, WI, USA

Category
System Administration
IT & Security
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Arrowhead Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree in computer science or life sciences, other related field, or equivalent experience
  • 4+ years experience related to the administration, operation, and maintenance of Laboratory Information Management Systems (LIMS) Chromatography Data Systems, Spectrophotometry Systems, and ancillary/supporting laboratory systems in a GxP environment
  • Advanced knowledge of computer programs (e.g., MS Word, MS Excel, computerized data acquisition systems)
  • Ability to multi-task and participate in multiple projects and department initiatives concurrently
  • Ability to produce high quality results while working under the pressure of strict deadlines
  • Ability to function effectively independently, as necessary, and work with others to achieve team goals
Responsibilities
  • Support and system administration for identified applications
  • Perform investigation and resolution efforts for technical and business process issues
  • Communicate technical issues and resolutions with users and department managers
  • Escalate issues to application vendors as necessary
  • Troubleshoot and collaborate with end users and departmental managers
  • Maintain a high level of functional subject matter knowledge for the assigned applications
  • Perform other duties as assigned
  • Perform periodic application review and management of user access
  • Represent the application documentation in client and regulatory audits
  • Contribute to audit finding responses
  • Contribute to computer system validation and computer software assurance projects, including application change control as required by GxP, Arrowhead Pharmaceuticals policies and SDLC
  • Draft CSV/CSA documentation for example, validation plans, design specifications, traceability matrices, functional user and user requirements specifications, test scripts, deviations, and summary reports
  • Establish open communication between the business and Information Systems and Informatics
  • Triage escalation of technical issues to Information Systems and Informatics
  • Perform updates to the global systems inventory for applications
  • Coordinate release of new versions of applications into respective environments including Development, Testing and Production environments
  • Develop business scenarios to test applications
  • Verify installation and operation of applications
  • Document analysis and/or testing related to infrastructure changes. (e.g., operating system patches, significant network changes)
Desired Qualifications
  • Extensive experience validating and supporting Agilent laboratory systems (Openlab, Chemstation, Cary UV systems)
  • Excellent experience with pharmaceutical/CRO industry regulations, standards, and guidelines (GxP, CSV/CSA validation, 21 CFR Part 11, EU Annex 11, SDLC)
  • Experience with regulated environment asset management applications and environment monitor applications
  • Computer System Validation, 21 CFR Part 11, Annex 11, and GxP
  • Pharmaceutical or CRO experience
  • Project Management certification
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective gene silencing. This method allows for significant and lasting reductions in the activity of harmful genes, which can help in managing diseases like cystic fibrosis and hepatitis B. Arrowhead differentiates itself from competitors by focusing specifically on RNAi-based therapies and leveraging a wide range of RNA chemistries and delivery methods. The company's goal is to address unmet medical needs by providing new treatment options for genetic disorders that currently lack effective therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
  • Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
  • Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.

What critics are saying

  • Increased competition from companies like Alnylam may impact Arrowhead's market share.
  • Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
  • Reliance on strategic financing may lead to increased debt obligations for Arrowhead.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

BioSpace
Apr 15th, 2025
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.